Tracers / [177Lu]Lu-DOTA-exendin-4
[177Lu]Lu-DOTA-exendin-4
Also written as [Lu-177]Lu-DOTA-exendin-4
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated exendin-4 peptide (GLP-1 receptor targeting radiopeptide)
- Target / mechanism
- GLP-1 receptor (GLP-1R) PMID 37265006
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-dotaexendin4/">ga68-dotaexendin4</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >95% | DOTA-exendin-4 piCHEM, Raaba-Grambach, Austria | 37265006 2023 Mol Pharm DOTA-exendin-4 and DOTA-MI-exendin-4 were labeled with 177Lu by incubating |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-exendin-4, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 37265006: 'DOTA-exendin-4, Lys40[Mep((S-)DOTA-Met-Ile-Mal-)]exendin-4'.